Navigation Links
Amarin Provides 2010 Year-End Review to Shareholders
Date:1/31/2011

ata set at an appropriate scientific conference and securing various publications of the data
  • Announcement of the top-line data for the ANCHOR trial in the second quarter of 2011
  • Filing an NDA for AMR101 in 2011
  • Building a foundation for commercializing AMR101
  • Qualifying additional suppliers to establish greater supply diversification and capacity in preparation for AMR101 launch

  • We believe that the positive results from the MARINE trial support the significant potential for AMR101 in multiple relatively untapped markets.  Today, approximately 3.8 million patients in the U.S. alone are diagnosed with very high triglyceride levels over 500 mg/dL, an indication for which only one other omega-3 based drug is approved in the U.S. This prescription omega-3-based drug accounts for U.S. sales of approximately $1.0 billion.

    Additionally, approximately 36 million patients are currently diagnosed with high triglyceride levels between 200 and 500 mg/dL, a patient population for which there is no approved omega-3-based drug.  AMR101 is currently under investigation for this indication in the ongoing ANCHOR study.  Amarin will evaluate all options for seeking regulatory approval for, and commercializing, AMR101, with the goal of maximizing the global sales opportunity for AMR101 and, as a result, shareholder value.  

    ClosingI would like to thank our investors for their continued support as we move forward to seek regulatory approval for and commercialize AMR101. We will continue to make the Amarin management team available to our investors by participating in various investor conferences throughout the year. We have already begun this year with meetings and a presentation at the JPMorgan Healthcare Conference in San Francisco and are scheduled to present at a number of presentations in the first and second quarter of 2011. These include; Leerink Swann Hot Topics Conference (New York City, Febru
    '/>"/>

    SOURCE Amarin Corporation plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
    2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
    3. Amarin to Present at UBS Life Sciences Conference
    4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
    5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
    6. Amarin Prices Public Offering of American Depositary Shares
    7. Amarin Announces Underwriters Exercise of Over-Allotment Option
    8. Amarin Announces Successful Completion of Offering of American Depositary Shares
    9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
    10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
    (Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
    (Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
    Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... SUNNYVALE, Calif. , June 22 Xoft, ... tube technology, today announced the integration of its Axxent® ... a state of the art, fully comprehensive breast center ... of breast cancer. The Pink Lotus Breast Center is ...
    ... June 22 The SCOOTER Store today announced a major ... the delivery of a power wheelchair to Earvin Thompson of ... assistance from the nation,s leading provider of power mobility equipment, will enjoy ... , , ...
    Cached Medicine Technology:Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4
    (Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
    (Date:4/23/2014)... the popular Swedish children,s TV show Bolibompa, but ... new study from the University of Gothenburg explores ... as well as the link between young children,s ... Steingerdur Olafsdottir,s doctoral thesis focuses on the presence ... show Bolibompa. Healthy foods dominated in the Swedish-produced ...
    (Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
    (Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
    (Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
    Breaking Medicine News(10 mins):Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
    ... Independence Day, NEW YORK, March 28 ... its website Healingstartswithus.net to create a,grassroots online network ... reach 1 million pledges by Independence Day, July ... an overflowing crowd of community,civic, social, political leaders ...
    ... Conseco, Inc. (NYSE:,CNO) announced today that it has ... ended December 31, 2007 with the Securities and Exchange,Commission., ... for 2007 was $194.0,million, compared to the $210.1 million ... results. The reported net loss applicable to,common stock for ...
    ... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
    ... fever, sometimes as high as 104 or 105 degrees, and ... hospital runs test after test, specialists are brought in, but ... one knows how many go through this cyclical nightmare. ... any obvious symptoms and dont respond to antibiotics or fever ...
    ... stem cells to be engineered into new blood vessels or ... the hair on their patients heads, according to new research ... , Engineering blood vessels for bypass surgery, promoting the ... using stem cells obtained from the most accessible source -- ...
    ... Pa., March 28 Governor Edward G.,Rendell today released ... which,explains the March 31 deadline for MCare fund assessment ... I wrote informing you that the state was in ... 10 years while providing,access to affordable health care for ...
    Cached Medicine News:Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2
    Indications For Usage: , ,For use during pulmonary lung function testing...
    ... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
    circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
    ... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
    Medicine Products: